PMID: 29798983
Gusev et al./PubMed/2019
Why It Matters
This Russian study caught my attention because it tests a nootropic peptide (semax) that some biohackers use for cognitive enhancement—but in actual stroke patients. The results suggest it might support neuroplasticity through BDNF, though this is a small study from one country with limited details on methodology. Not something to DIY, but interesting evidence that peptides affecting brain-derived neurotrophic factor could have real functional outcomes.
Key Findings
- Semax treatment was associated with increased plasma BDNF levels in stroke patients across different recovery stages
- Patients receiving semax showed improvements in motor performance compared to standard rehabilitation alone
- Barthel index scores (measuring independence in daily activities) improved more in semax-treated groups
- Effects varied by stroke stage, with timing of treatment potentially influencing outcomes
- The study was relatively small and conducted in Russia where semax is an approved pharmaceutical (not available in US/EU)
Read the Paper↗PMID: 29798983